Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Sponsor
Zhengzhou University
Study ID
NCT03631862
Phase
PHASE4
Status
Unknown

Conditions

  • Newly Diagnosed Peripheral T-cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
14 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
  • CHOP Regimen — DRUG
    CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)

Study Details

The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Key Dates

Start date
Sep 1, 2018
Status verified
Aug 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib combined with CHOP regimen
    Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
  • Experimental: CHOP regimen
    CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5

Primary Outcome Measure

PFS [ Time Frame: up to end of follow-up-phase (approximately 24 months) ]

Central Contacts